We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $177M
1-Year Est. Return 91.13%
This Fund
S&P 500
This Quarter Est. Return
+16.86%
1 Year Est. Return
+91.13%
3 Year Est. Return
+230.7%
5 Year Est. Return
+260.67%
10 Year Est. Return
+2,169.5%
AUM
$177M
AUM Growth
-$72.5M
Cap. Flow
+$12.6M
Cap. Flow %
7.11%
Top 10 Hldgs %
44.39%
Holding
107
New
24
Increased
24
Reduced
27
Closed
20

Top Buys

Rank Stock Value
1
ELOX
Eloxx Pharmaceuticals
ELOX
+$5.07M
2
EDSA icon
Edesa Biotech
EDSA
+$3.85M
3
INDV icon
Indivior Pharmaceuticals
INDV
+$3.63M
4
CABA icon
Cabaletta Bio
CABA
+$2.85M
5
MSLE
Satellos Bioscience
MSLE
+$2.69M

Top Sells

Rank Stock Value
1
TENX icon
Tenax Therapeutics
TENX
+$4.03M
2
ZVRA icon
Zevra Therapeutics
ZVRA
+$2.46M
3
XOMA
Xoma
XOMA
+$2.18M
4
ABEO icon
Abeona Therapeutics
ABEO
+$1.04M
5
IKT icon
Inhibikase Therapeutics
IKT
+$1M

Sector Composition

Rank Sector Weight
1 Healthcare 74.11%
2 Miscellaneous 25.89%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACET icon
26
Adicet Bio
ACET
$88.3M
$2.12M 1.2%
245,518
+23,563
+11% +$186K
XERS icon
27
CALL
Xeris Biopharma Holdings
XERS
$1.57B
$2.1M 1.18%
280,000
– –
TELA icon
28
TELA Bio
TELA
$35.1M
$2M 1.13%
2,662,427
+45,175
+2% +$37K
AYTU icon
29
AYTU BioPharma
AYTU
$24.5M
$1.96M 1.11%
912,921
+120,632
+15% +$285K
CRIS icon
30
Curis
CRIS
$3.32M
$1.73M 0.98%
165,609
-20,711
-11% -$212K
SPRB
31
Spruce Biosciences
SPRB
$166M
$1.55M 0.88%
+28,795
New +$1.61M
HRTX icon
32
CALL
Heron Therapeutics
HRTX
$62.7M
$1.5M 0.85%
1,000,000
– –
SIBN icon
33
CALL
SI-BONE Inc
SIBN
$835M
$1.5M 0.85%
100,000
– –
OKYO
34
OKYO Pharma
OKYO
$81.3M
$1.29M 0.73%
862,996
+12,996
+2% +$20.8K
NMRA icon
35
CALL
Neumora Therapeutics
NMRA
$254M
$1.25M 0.71%
500,000
– –
KTTA icon
36
Pasithea Therapeutics
KTTA
$19.4M
$1.13M 0.64%
2,201,468
+1,370,167
+165% +$943K
SLGL icon
37
Sol-Gel Technologies
SLGL
$230M
$1.07M 0.61%
14,469
-13,309
-48% -$977K
LUNG icon
38
Pulmonx
LUNG
$97.1M
$1.06M 0.6%
815,436
+47,148
+6% +$65K
XFOR icon
39
X4 Pharmaceuticals
XFOR
$401M
$1.05M 0.59%
224,989
-110,320
-33% -$453K
ARDX icon
40
CALL
Ardelyx
ARDX
$958M
$1.05M 0.59%
150,000
– –
DCTH icon
41
CALL
Delcath Systems
DCTH
$572M
$1M 0.56%
100,000
– –
INAB icon
42
IN8bio
INAB
$11.4M
$980K 0.55%
695,287
+31,875
+5% +$48K
MLTX icon
43
MoonLake Immunotherapeutics
MLTX
$1.29B
$974K 0.55%
+50,000
New +$906K
QNRX
44
Quoin Pharmaceuticals
QNRX
$15.8M
$966K 0.54%
199,486
+146,026
+273% +$788K
MXCT icon
45
MaxCyte
MXCT
$130M
$924K 0.52%
751,606
-253,067
-25% -$252K
PHAT icon
46
Phathom Pharmaceuticals
PHAT
$732M
$922K 0.52%
85,010
+35,000
+70% +$399K
AZTR icon
47
Azitra
AZTR
$10.9M
$887K 0.5%
+5,285,476
New +$1.14M
CNTB
48
Connect Biopharma Holdings
CNTB
$122M
$867K 0.49%
364,254
+54,254
+18% +$132K
HELP
49
Cybin Inc
HELP
$860M
$855K 0.48%
129,280
-4,780
-4% -$23.9K
RARE icon
50
Ultragenyx Pharmaceutical
RARE
$1.46B
$835K 0.47%
+25,000
New +$621K
1
2
3 4 5

Similar funds

RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
MSA
Marathon Strategic Advisors Pittsburgh, Pennsylvania $177M AUM 66.85% 1-Year Est. Return
HF
Holcombe Financial Atlanta, Georgia $177M AUM 13.35% 1-Year Est. Return
BFAG
Blackston Financial Advisory Group The Villages, Florida $177M AUM 21.44% 1-Year Est. Return
CWP
Clark Wealth Partners O'fallon, Illinois $177M AUM 22.36% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
CMP
Christine Messmer PC Collegeville, Pennsylvania $177M AUM
JESC
J.E. Simmons & Co Dallas, Texas $177M AUM

Stonepine Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Stonepine Capital Management held 107 positions worth $177M, down 29% from $250M the previous quarter. Its ten largest holdings account for 44% of the portfolio.

Stonepine Capital Management deployed $12.6M of net new capital in Q2 2026, opening 24 new positions and adding to 24 existing holdings. Its largest new stake was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 46% a quarter earlier, followed by Miscellaneous.

On the sell side, the largest reduction was Tenax Therapeutics, an estimated $4.03M trimmed.

  • Stonepine Capital Management's largest Q2 2026 buy was Eloxx Pharmaceuticals: 397,160 shares worth $5.51M.
  • Stonepine Capital Management added most to Edesa Biotech in Q2 2026, an estimated $3.85M increase.
  • Stonepine Capital Management's biggest Q2 2026 reduction was Tenax Therapeutics, cutting an estimated $4.03M.
  • Stonepine Capital Management fully exited Xoma in Q2 2026, selling an estimated $2.18M.
  • Stonepine Capital Management's ten largest holdings make up 44% of its $177M portfolio in Q2 2026.
  • Stonepine Capital Management opened 24 new positions and closed 20 in Q2 2026.
  • Stonepine Capital Management's portfolio value fell 29% quarter-over-quarter to $177M.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.